GE HealthCare launches new SIGNA MAGNUS MR scanner to expand neuroscience field

GE HealthCare has unveiled SIGNA MAGNUS, a US FDA 510(k) pending head-only magnetic resonance (MR) scanner designed to explore advancements in neuroscience, which have been restricted by the performance limitations of conventional whole-body MR systems.

Neuroscience, particularly in the study of psychiatric diseases and neurological disorders such as Alzheimer’s, has been constrained by technological and biological limitations, leaving many aspects of the brain structure and functionality largely unexplored.

SIGNA MAGNUS is a part of GE HealthCare’s advanced 3.0T MR imaging device, specifically designed for the highest standards of neurological and oncological research for head-only imaging, to offer detail and clarity that allows for an in-depth exploration of brain microstructure, microvasculature, and function. Through SIGNA MAGNUS, GE HealthCare will help to empower neuroscientists, neurologists, neuroradiologists and oncologists to transcend barriers, to enhance the diagnosis, understanding, and treatment of complex diseases.

This advanced system offers superior gradient performance with its HyperG gradient technology, featuring 300 mT/m and 750 T/m/s, enabling the detection of fine details that were previously unattainable. Researchers can fully utilise SIGNA MAGNUS for advanced anatomical, diffusion and functional techniques, amplified by the latest deep-learning algorithms that GE HealthCare has to offer. SIGNA MAGNUS is designed to help in studying new parameters and biomarkers. Its innovative asymmetric gradient design allows for remarkable diffusion performance, achieving extremely high B-value diffusion with short echo times (TEs), which further refines the understanding of neural architecture. Additionally, many GE HealthCare 3.0T systems are upgradable to SIGNA MAGNUS, which will help potential customers to save on capital costs.